Fig. 4

N-803 monotherapy and N-803 + αPD-L1 combination promote an activated NK cell phenotype and increase function. Mice were implanted with 4T1 tumors as in Fig. 1 and treated on days 9 and 13 with N-803 and/or αPD-L1 on days 9, 11, and 13. a-d NK cells were examined by flow cytometry in the primary tumor, lung vasculature, and spleen 24 h after the last treatment. Graphs show NK cell number (a) and frequencies of NKG2D⁺ (b), Ki67⁺ (c), and Granzyme B⁺ (d) NK cells. e Purified splenic NK cells were co-cultured with ¹¹¹In-labeled Yac-1 target cells at a 100:1 effector-to-target (E:T) ratio for 18 h. ¹¹¹In release was measured to determine cytotoxic function. All graphs show mean ± SD. Data combined from 2 to 3 independent experiments, n = 4–5 mice/group per experiment